Upload
buck-hamilton
View
214
Download
2
Embed Size (px)
Citation preview
EEOICPA Compensation Results (through March
2004)
Russ Henshaw, MSEpidemiologist
NIOSH/Office of CompensationAnalysis & Support
Cincinnati, OH
Completed Claim Results:Important Caveats
Results are through March 31, 2004 Includes only those cases in which
NIOSH has received notice from DOL of an official compensation decision (~ 2/3 of cases)
May NOT be predictive of future results Unless otherwise noted, results are for
claims with only one primary cancer
Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model
Cancer Model (ICD-9 Code)
Total
Compensated
Oral Cavity and Pharynx (140-149)
23 4 (17%)
Esophagus (150) 19 0 (0%)
Stomach (151) 21 0 (0%)
Colon (153) 78 1 (1%)
Rectum (154) 27 0 (0%)
Completed Claims: Proportion That Were Compensable, by
NIOSH-IREP Cancer Model (Cont.)
Cancer Model (ICD-9 Code)
Total
Compensated
All digestive (150-159) 3 0 (0%)
Liver (155.0) 7 5 (71%)
Gallbladder (155.1, 156) 3 1 (33%)
Pancreas (157) 43 0 (0%)
Lung (162) 230 209 (91%)
Completed Claims: Proportion That Were Compensable, by
NIOSH-IREP Cancer Model (Cont.)
Cancer Model (ICD-9 Code)
Total
Compensated
Other respiratory (160, 161, 163-165)
19 6 (32%)
Bone (170) 3 1 (33%)
Connective tissue (171) 13 0 (0%)
Malignant melanoma (172) 19 3 (16%)
Non-melanoma skin-Basal Cell (173)
25 11 (44%)
Completed Claims: Proportion That Were Compensable, by
NIOSH-IREP Cancer Model (Cont.)
Cancer Model (ICD-9 Code)
Total Compensated
Non-melanoma skin-Squamous Cell (173)
16 1 (6%)
Breast (174-175) 69 1 (1%)
Ovary (183) 2 0 (0%)
Female genitalia, excluding ovary (179-182, 184)
14 0 (0%)
All male genitalia (185-187) 219 0 (0%)
Completed Claims: Proportion That Were Compensable, by
NIOSH-IREP Cancer Model (Cont.)
Cancer Model (ICD-9 Code)
Total
Compensated
Bladder (188) 42 2 (5%)
Urinary organs, excluding bladder (189)
11 5 (45%)
Eye (190) 2 0 (0%)
Nervous system (191-192) 33 0 (0%)
Thyroid (193) 14 0 (0%)
Completed Claims: Proportion That Were Compensable, by
NIOSH-IREP Cancer Model (Cont.)
Cancer Model (ICD-9 Code)
Total Compensated
Other endocrine glands (194) 2 0 (0%)
Other and ill-defined sites (195) 0 N/ALymphoma & multiple myeloma (200-203)
90 2 (2%)
Leukemia, excluding CLL (204-208, excluding 204.1)
6 5 (83%)
Acute Lymphocytic Leukemia (204.0)
3 3 (100%)
Completed Claims: Proportion That Were Compensable, by
NIOSH-IREP Cancer Model (Cont.)
Cancer Model (ICD-9 Code)
Total
Compensated
Acute Myeloid Leukemia (205.0) 8 3 (38%)
Chronic Myeloid Leukemia (205.1)
7 5 (71%)
Claims with unknown primary cancer
28 24 (86%)
Claims with multiple primary cancers
226 146 (65%)
All Completed Claims 1325
438 (33%)
Compensability Rate, by Cancer Model (10 or More Completed
Cases)91%
45%32%
17% 16%
44%
0%10%20%30%40%50%60%70%80%90%
100%
Compensability Rate, by Cancer Model (10 or More Completed
Cases)
6% 5% 1% 1%2%0%
10%20%30%40%50%60%70%80%90%
100%
SCC Bladder Lym &MM
Breast Colon
Compensability Rate, by Cancer Model (10 or More Completed
Cases) 0% (no compensable cases):
Esophagus Stomach Rectum Pancreas Connective tissue Female genitalia, excluding ovary All male genitalia Nervous system Thyroid
Compensability Rates for “Unknown Primary” and “Multiple
Primary” Claims86%
65%
0%10%20%30%40%50%60%70%80%90%
100%
Unknown Primary Multiple Primary
Proportion of Claims That Were Compensable, by Years Worked
10%15%
40%
50%
29%
0%
10%
20%
30%
40%
50%
60%
<10Years
10-19Years
20-29Years
30-39Years
40+Years
Proportion of Claims That Were Compensable, by Age at
Diagnosis
0%
10%
22%28%
34%
54%
14%
0%
10%
20%
30%
40%
50%
60%
Aged20-29
Aged30-39
Aged40-49
Aged50-59
Aged60-69
Aged70-79
Aged80+
Lung Cancer Compensability (Single Primary Cancer) by
Smoking Status86%
91%
0%10%20%30%40%50%60%70%80%90%
100%
Never Smoked Ever Smoked
Lung Cancer Compensability (Single Primary Cancer) by
Smoking Status86%
95% 92%
75%
50%
100%91%
0%10%20%30%40%50%60%70%80%90%
100%
Compensability Rate by Gender (All Completed
Claims)
37%
4%
0%10%20%30%40%50%60%70%80%90%
100%
Males Females
Summary Some initial surprises, but current results
are skewed: By dose reconstruction “efficiency process” Possibly by incomplete data (we are awaiting
official decisions from DOL for about 1/3 of all completed cases)
Data will continue to be monitored for trends & anomalies
Results are not predictive of future claims